Literature DB >> 28534193

Antagonist-perturbation mechanism for activation function-2 fixed motifs: active conformation and docking mode of retinoid X receptor antagonists.

Motonori Tsuji1.   

Abstract

HX531, which contains a dibenzodiazepine skeleton, is one of the first retinoid X receptor (RXR) antagonists. Functioning via RXR-PPARγ heterodimer, this compound is receiving a lot of attention as a therapeutic drug candidate for diabetic disease controlling differentiation of adipose tissue. However, the active conformation of HX531 for RXRs is not well established. In the present study, quantum mechanics calculations and molecular mechanical docking simulations were carried out to precisely study the docking mode of HX531 with the human RXRα ligand-binding domain, as well as to provide a new approach to drug design using a structure-based perspective. It was suggested that HX531, which has the R configuration for the bent dibenzodiazepine plane together with the equatorial configuration for the N-methyl group attached to the nitrogen atom in the seven-membered diazepine ring, is a typical activation function-2 (AF-2) fixed motif perturbation type antagonist, which destabilizes the formation of AF-2 fixed motifs. On the other hand, the docking simulations supported the experimental result that LG100754 is an RXR homodimer antagonist and an RXR heterodimer agonist.

Entities:  

Keywords:  AF-2 fixed motifs; Docking simulation; HX531; LG100754; Quantum mechanics; Retinoid X receptor

Mesh:

Substances:

Year:  2017        PMID: 28534193     DOI: 10.1007/s10822-017-0025-6

Source DB:  PubMed          Journal:  J Comput Aided Mol Des        ISSN: 0920-654X            Impact factor:   3.686


  18 in total

1.  A mutation mimicking ligand-induced conformational change yields a constitutive RXR that senses allosteric effects in heterodimers.

Authors:  V Vivat; C Zechel; J M Wurtz; W Bourguet; H Kagechika; H Umemiya; K Shudo; D Moras; H Gronemeyer; P Chambon
Journal:  EMBO J       Date:  1997-09-15       Impact factor: 11.598

2.  The phantom ligand effect: allosteric control of transcription by the retinoid X receptor.

Authors:  I G Schulman; C Li; J W Schwabe; R M Evans
Journal:  Genes Dev       Date:  1997-02-01       Impact factor: 11.361

3.  Identification of the first retinoid X, receptor homodimer antagonist.

Authors:  S S Canan Koch; L J Dardashti; J J Hebert; S K White; G E Croston; K S Flatten; R A Heyman; A M Nadzan
Journal:  J Med Chem       Date:  1996-08-16       Impact factor: 7.446

4.  Asymmetry in the PPARgamma/RXRalpha crystal structure reveals the molecular basis of heterodimerization among nuclear receptors.

Authors:  R T Gampe; V G Montana; M H Lambert; A B Miller; R K Bledsoe; M V Milburn; S A Kliewer; T M Willson; H E Xu
Journal:  Mol Cell       Date:  2000-03       Impact factor: 17.970

5.  Danthron functions as a retinoic X receptor antagonist by stabilizing tetramers of the receptor.

Authors:  Haitao Zhang; Rong Zhou; Li Li; Jing Chen; Lili Chen; Chenjing Li; Hong Ding; Liang Yu; Lihong Hu; Hualiang Jiang; Xu Shen
Journal:  J Biol Chem       Date:  2010-11-17       Impact factor: 5.157

6.  Inhibition of RXR and PPARgamma ameliorates diet-induced obesity and type 2 diabetes.

Authors:  T Yamauchi; H Waki; J Kamon; K Murakami; K Motojima; K Komeda; H Miki; N Kubota; Y Terauchi; A Tsuchida; N Tsuboyama-Kasaoka; N Yamauchi; T Ide; W Hori; S Kato; M Fukayama; Y Akanuma; O Ezaki; A Itai; R Nagai; S Kimura; K Tobe; H Kagechika; K Shudo; T Kadowaki
Journal:  J Clin Invest       Date:  2001-10       Impact factor: 14.808

7.  Docking simulations suggest that all-trans retinoic acid could bind to retinoid X receptors.

Authors:  Motonori Tsuji; Koichi Shudo; Hiroyuki Kagechika
Journal:  J Comput Aided Mol Des       Date:  2015-09-18       Impact factor: 3.686

8.  Activation of specific RXR heterodimers by an antagonist of RXR homodimers.

Authors:  D S Lala; R Mukherjee; I G Schulman; S S Koch; L J Dardashti; A M Nadzan; G E Croston; R M Evans; R A Heyman
Journal:  Nature       Date:  1996-10-03       Impact factor: 49.962

9.  The "Phantom Effect" of the Rexinoid LG100754: structural and functional insights.

Authors:  Yoshiteru Sato; Nick Ramalanjaona; Tiphaine Huet; Noelle Potier; Judit Osz; Pierre Antony; Carole Peluso-Iltis; Pierre Poussin-Courmontagne; Eric Ennifar; Yves Mély; Annick Dejaegere; Dino Moras; Natacha Rochel
Journal:  PLoS One       Date:  2010-11-30       Impact factor: 3.240

10.  Identifying the receptor subtype selectivity of retinoid X and retinoic acid receptors via quantum mechanics.

Authors:  Motonori Tsuji; Koichi Shudo; Hiroyuki Kagechika
Journal:  FEBS Open Bio       Date:  2017-02-05       Impact factor: 2.693

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.